[go: up one dir, main page]

PT1317273E - Utilizacao de quimera il-6r/il-6 na doenca de huntington - Google Patents

Utilizacao de quimera il-6r/il-6 na doenca de huntington

Info

Publication number
PT1317273E
PT1317273E PT01972039T PT01972039T PT1317273E PT 1317273 E PT1317273 E PT 1317273E PT 01972039 T PT01972039 T PT 01972039T PT 01972039 T PT01972039 T PT 01972039T PT 1317273 E PT1317273 E PT 1317273E
Authority
PT
Portugal
Prior art keywords
chimera
huntington
disease
derivative
mutein
Prior art date
Application number
PT01972039T
Other languages
English (en)
Inventor
Nicole Deglon
Patrick Aebischer
Jean-Charles Bensadoun
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of PT1317273E publication Critical patent/PT1317273E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/204IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
PT01972039T 2000-09-14 2001-09-10 Utilizacao de quimera il-6r/il-6 na doenca de huntington PT1317273E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00120045 2000-09-14

Publications (1)

Publication Number Publication Date
PT1317273E true PT1317273E (pt) 2006-09-29

Family

ID=8169836

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01972039T PT1317273E (pt) 2000-09-14 2001-09-10 Utilizacao de quimera il-6r/il-6 na doenca de huntington

Country Status (13)

Country Link
US (3) US20040057928A1 (pt)
EP (1) EP1317273B1 (pt)
JP (1) JP5030364B2 (pt)
AT (1) ATE324906T1 (pt)
AU (2) AU9184901A (pt)
CA (1) CA2419954C (pt)
CY (1) CY1105116T1 (pt)
DE (1) DE60119347T2 (pt)
DK (1) DK1317273T3 (pt)
ES (1) ES2262680T3 (pt)
IL (2) IL154777A0 (pt)
PT (1) PT1317273E (pt)
WO (1) WO2002022149A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
WO2004037281A1 (en) * 2002-10-24 2004-05-06 The University Of British Columbia Methods for neuroprotection
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
JP4878553B2 (ja) * 2003-06-12 2012-02-15 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド オリゴデンドロサイト分化の促進
AU2004279895A1 (en) 2003-10-10 2005-04-21 Xencor, Inc Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
NZ630848A (en) 2012-06-08 2016-07-29 Alkermes Inc Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
US5792900A (en) * 1991-10-21 1998-08-11 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
WO1999032646A1 (en) * 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
JP4859153B2 (ja) * 1999-02-25 2012-01-25 東ソー株式会社 新規神経系細胞分化促進剤
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
EP1317273A1 (en) 2003-06-11
JP2004508409A (ja) 2004-03-18
US20100166703A1 (en) 2010-07-01
US8329654B2 (en) 2012-12-11
DK1317273T3 (da) 2006-09-04
IL154777A0 (en) 2003-10-31
US20070172454A1 (en) 2007-07-26
CY1105116T1 (el) 2009-11-04
DE60119347D1 (de) 2006-06-08
US20040057928A1 (en) 2004-03-25
CA2419954A1 (en) 2002-03-21
AU9184901A (en) 2002-03-26
AU2001291849B2 (en) 2005-11-24
CA2419954C (en) 2012-01-03
IL154777A (en) 2010-11-30
DE60119347T2 (de) 2007-02-22
JP5030364B2 (ja) 2012-09-19
WO2002022149A1 (en) 2002-03-21
ES2262680T3 (es) 2006-12-01
EP1317273B1 (en) 2006-05-03
ATE324906T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
DOP2002000429A (es) Imidazotriazinas
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
BR0213358A (pt) Uso de flibanserina
NO330934B1 (no) Flytende farmasoytisk preparat samt anvendelse og fremstilling derav.
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
BRPI0410029A (pt) dihidroquinazolinas substituìdas
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BRPI0414215A (pt) tienopirazóis
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
BR0012291A (pt) Fenoxifluorpirimidinas
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
PT1317273E (pt) Utilizacao de quimera il-6r/il-6 na doenca de huntington
BR9913337A (pt) Derivados tan-1057
SE0002729D0 (sv) Novel compound form
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
BR0210910A (pt) Derivados de imidazotriazinonas e sua aplicação contra processos inflamatórios e/ou doenças imunes
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
SE0000303D0 (sv) Novel compounds
DK1012286T3 (da) Allelvariant af humant STAT3
MEP39708A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine